Literature DB >> 16128917

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.

Ranajit Pal1, Shixia Wang, V S Kalyanaraman, B C Nair, Stephen Whitney, Timothy Keen, Lindsey Hocker, Lauren Hudacik, Nicolas Rose, Anthony Cristillo, Innocent Mboudjeka, Siyuan Shen, Te-Hui Wu-Chou, David Montefiori, John Mascola, Shan Lu, Phillip Markham.   

Abstract

Immunization of macaques with multivalent DNA encoding gp120 genes from HIV-1 subtypes A, B, C and E and a gag gene followed by boosting with homologous gp120 proteins elicited strong anti-gp120 antibodies capable of neutralizing homologous and to a lesser degree heterologous HIV-1 isolates. Both Env- and Gag-specific cell mediated immune (CMI) responses were detected in the immunized animals. Following rectal challenge with an SHIV isolate encoding HIV-1(Ba-L)env, plasma viremia in the infected immunized animals was significantly lower than that observed in the naïve animals. Further, one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIV(Ba-L).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128917      PMCID: PMC2362402          DOI: 10.1111/j.1600-0684.2005.00120.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  29 in total

1.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  HIV-1 prophylactic vaccine trials in Thailand.

Authors:  Punnee Pitisuttithum
Journal:  Curr HIV Res       Date:  2005-01       Impact factor: 1.581

3.  Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Authors:  S W Barnett; S Rajasekar; H Legg; B Doe; D H Fuller; J R Haynes; C M Walker; K S Steimer
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

4.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 7.  Prospects for vaccine protection against HIV-1 infection and AIDS.

Authors:  Norman L Letvin; Dan H Barouch; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

8.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

Authors:  Ranajit Pal; Brian Taylor; J Scott Foulke; Ruth Woodward; Michael Merges; Rob Praschunus; Andrew Gibson; Marvin Reitz
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more
  33 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 2.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

3.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

Review 4.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 5.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

6.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

7.  Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.

Authors:  Rachel Buglione-Corbett; Kimberly Pouliot; Robyn Marty-Roix; Wei Li; Kim West; Shixia Wang; Adriana Baz Morelli; Egil Lien; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

Review 8.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

9.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 10.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.